🏛️ Verified NIH Record • Updated 2026-06-10

First in Human Study of AZD9592 in Solid Tumors (NCT05647122)

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.

Who can join: Review the eligibility criteria below.

Location: Research Site — Duarte, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (46 Sites)

Showing the first 25 of 46 sites.

  • Research Site — Duarte, California
  • Research Site — North Haven, Connecticut
  • Research Site — Washington D.C., District of Columbia
  • Research Site — Chicago, Illinois
  • Research Site — Baltimore, Maryland
  • Research Site — Baltimore, Maryland
  • Research Site — Milford, Massachusetts
  • Research Site — Mineola, New York
  • Research Site — New York, New York
  • Research Site — New York, New York
  • Research Site — New York, New York
  • Research Site — Philadelphia, Pennsylvania
  • Research Site — Providence, Rhode Island
  • Research Site — Houston, Texas
  • Research Site — Fairfax, Virginia
  • Research Site — Kogarah,
  • Research Site — Melbourne,
  • Research Site — Edmonton, Alberta
  • Research Site — Toronto, Ontario
  • Research Site — Beijing,
  • Research Site — Chongqing,
  • Research Site — Guangzhou,
  • Research Site — Wuhan,
  • Research Site — Marseille,
  • Research Site — Rennes,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumours

Explore by condition: All Advanced Solid Tumours clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗